Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Xiangjun Kong, Qianru Zhang, Yunfeng Lai, Hao Hu, Xin Chen & Yuanjia Hu. (2018) Global patent landscape of programmed cell death 1: implications of the rapid expansion. Expert Opinion on Therapeutic Patents 28:1, pages 69-80.
Read now
Read now
Articles from other publishers (15)
Joab Williamson, Juho Jalkanen & Maria Lahtinen. (2023) Small pharma vendor management practices in clinical trials: A case study within Faron Pharmaceuticals. Drug Discovery Today 28:6, pages 103553.
Crossref
Crossref
Aniek Dane, Soedaba Ashraf, James Timmis, Monique Bos, Carin Uyl-de Groot & P Hugo M van der Kuy. (2022) Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives. BMJ Open 12:2, pages e055165.
Crossref
Crossref
Oscar Tamburis & Isabella Bonacci. (2019) Clusters and communities: raising the bar towards open innovation 2.0 paradigms. International Journal of Pharmaceutical and Healthcare Marketing 13:3, pages 288-305.
Crossref
Crossref
Donald J. AbrahamRoland E. Dolle, Laurel K. McGrane, James W. Janetka, Jared T. Hammill, Rodney Kiplin Guy, Anjan Debnath, Peter M. Cheuka, Claire Le Manach, Kelly Chibale, Ake Elhammer, Martin Handfield, Michael J. Dawson, Stefano Donadio, Jae H. Park & Alan Joslyn. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
95
.
Helene Markham JonesMarkham-JoMarkham-Jo, Ffion Curtis, Graham Law, Christopher Bridle, Dorothy Boyle & Tanweer Ahmed. (2020) Evaluating follow-up and complexity in cancer clinical trials (EFACCT): an eDelphi study of research professionals’ perspectives. BMJ Open 10:2, pages e034269.
Crossref
Crossref
Nada A Helal, Ola Elnoweam, Heba Abdullah Eassa, Ahmed M Amer, Mohamed Ashraf Eltokhy, Mohamed A Helal, Heba A Fayyaz & Mohamed Ismail Nounou. (2019) Integrated continuous manufacturing in pharmaceutical industry: current evolutionary steps toward revolutionary future. Pharmaceutical Patent Analyst 8:4, pages 139-161.
Crossref
Crossref
Michael S. Kinch & Ryan Moore. (2016) Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry. Cell Chemical Biology 23:6, pages 644-653.
Crossref
Crossref
Kenneth I Kaitin. (2015) The Quest to Develop New Medicines to Treat Alzheimer’s Disease: Present Trends and Future Prospects. Clinical Therapeutics 37:8, pages 1618-1621.
Crossref
Crossref
Ulrich A K Betz & Christian A Tidona. (2015) Outcubation—where incubation meets outsourcing. Nature Biotechnology 33:1, pages 20-21.
Crossref
Crossref
Kenneth A. Getz & Kenneth I. Kaitin. 2015. Re-Engineering Clinical Trials. Re-Engineering Clinical Trials
3
15
.
Matthew I. Bellgard, Mark W. Sleeman, Felix D. Guerrero, Sue Fletcher, Gareth Baynam, Jack Goldblatt, Yaffa Rubinstein, Callum Bell, Stephen Groft, Roberto Barrero, Alan H. Bittles, Stephen D. Wilton, Christopher E. Mason & Tarun Weeramanthri. (2014) Rare Disease Research Roadmap: Navigating the bioinformatics and translational challenges for improved patient health outcomes. Health Policy and Technology 3:4, pages 325-335.
Crossref
Crossref
Kenneth I. Kaitin. (2014) Integrated Partnerships and the Transformation of Pharmaceutical Research and Development. Clinical Therapeutics 36:10, pages 1346-1348.
Crossref
Crossref
Joseph A. DiMasi, Jennifer Kim & Kenneth A. Getz. (2014) The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle Times. Therapeutic Innovation & Regulatory Science 48:4, pages 482-487.
Crossref
Crossref
Clive G. Jackson. 2014. Reducing Drug Attrition. Reducing Drug Attrition
1
72
.
Peter R. Young. (2013) Perspective on the Discovery and Scientific Impact of p38 MAP Kinase. SLAS Discovery 18:10, pages 1156-1163.
Crossref
Crossref